Search research articles
Contact Us
Filters
Showing results (1-10 of 198) with videos related to
Page
of 20
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2006
Economic evaluation of cancer therapies: more and better studies will lead to better choices in cancer care
Carin A Uyl-de Groot
Current Opinion in Oncology
|
June 4, 2005
Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology?
Carin A Uyl-de Groot, Giuseppe Giaccone
Nature Reviews. Clinical Oncology
|
August 15, 2018
Reply to 'Economic comments on proposal for a novel cancer drug pricing model'
Carin A Uyl-de Groot, Bob Löwenberg
Nature Reviews. Clinical Oncology
|
May 9, 2018
Sustainability and affordability of cancer drugs: a novel pricing model
Carin A Uyl-de Groot, Bob Löwenberg
Nature Reviews. Clinical Oncology
|
June 30, 2018
Reply to 'Response to proposal for a novel cancer drug pricing model'
Carin A Uyl-de Groot, Bob Löwenberg
Pediatric Blood & Cancer
|
December 10, 2021
Comment on: "Premedication prior to PEG-asparaginase is cost effective in pediatric patients with acute lymphoblastic leukemia"
Wing H Tong, Carin A Uyl-De Groot
The Oncologist
|
January 10, 2013
Efficient allocation of novel agents in multiple myeloma: a work in progress
Jennifer G Gaultney, Carin A Uyl-de Groot
Journal of Cancer Policy
|
July 2, 2022
Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States
Remziye Zaim, Ken Redekop, Carin A Uyl-de Groot
Translational Oncology
|
April 16, 2022
Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
Remziye Zaim, Ken Redekop, Carin A Uyl-de Groot
Journal of Cancer Policy
|
January 2, 2023
Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer
Remziye Zaim, Ken Redekop, Carin A Uyl-de Groot
Page
of 20
Search research articles
Search
Showing results (1-10 of 198) with videos related to
Sort By:
Page
of 20
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2006
Economic evaluation of cancer therapies: more and better studies will lead to better choices in cancer care
Carin A Uyl-de Groot
Current Opinion in Oncology
|
June 4, 2005
Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology?
Carin A Uyl-de Groot, Giuseppe Giaccone
Nature Reviews. Clinical Oncology
|
August 15, 2018
Reply to 'Economic comments on proposal for a novel cancer drug pricing model'
Carin A Uyl-de Groot, Bob Löwenberg
Nature Reviews. Clinical Oncology
|
May 9, 2018
Sustainability and affordability of cancer drugs: a novel pricing model
Carin A Uyl-de Groot, Bob Löwenberg
Nature Reviews. Clinical Oncology
|
June 30, 2018
Reply to 'Response to proposal for a novel cancer drug pricing model'
Carin A Uyl-de Groot, Bob Löwenberg
Pediatric Blood & Cancer
|
December 10, 2021
Comment on: "Premedication prior to PEG-asparaginase is cost effective in pediatric patients with acute lymphoblastic leukemia"
Wing H Tong, Carin A Uyl-De Groot
The Oncologist
|
January 10, 2013
Efficient allocation of novel agents in multiple myeloma: a work in progress
Jennifer G Gaultney, Carin A Uyl-de Groot
Journal of Cancer Policy
|
July 2, 2022
Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States
Remziye Zaim, Ken Redekop, Carin A Uyl-de Groot
Translational Oncology
|
April 16, 2022
Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
Remziye Zaim, Ken Redekop, Carin A Uyl-de Groot
Journal of Cancer Policy
|
January 2, 2023
Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer
Remziye Zaim, Ken Redekop, Carin A Uyl-de Groot
Page
of 20